Clinical-stage ophthalmology Precise Bio is a clinical-stage regenerative medicine company focusing on bio-printed tissues and organs with an initial emphasis on ophthalmology, suggesting opportunities in ophthalmic device collaborations, regulatory-ready tissue constructs, and partnerships with eye care specialists.

Strategic partnerships Past collaborations with Carl Zeiss Meditec and participation in major healthcare conferences indicate a receptiveness to co-development and validation deals; explore co-funding, joint R&D programs, and contract manufacturing partnerships.

Funding and scale With debt financing secured and a revenue range in the low tens of millions, there is room for growth-focused financing conversations, milestones-based investment, and potential equity partnerships to accelerate platform scaling.

Global leadership Leadership has international ties (Israel and the United States) and active CEO participation in conferences, signaling openness to global strategic investors, multinational CROs, and cross-border supplier networks for materials and bio-printing tech.

Tech-enabled platform A scalable 4D bio-fabrication platform and state-of-the-art bio-printing capabilities present upsell opportunities for advanced bioprinting equipment, contract development/manufacturing services, and software/data integration for tissue fabrication workflows.